Form 4: Axsome Therapeutics COO Mark Jacobson Reports Stock Option and Unit Awards

Chief Operating Officer of Axsome Therapeutics, Mark L. Jacobson, reports the acquisition of stock options, restricted stock units (RSUs), and performance stock units (PSUs).

Summary

• Mark L. Jacobson, the Chief Operating Officer of Axsome Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On February 21, 2025, Jacobson was granted employee stock options for 10,875 shares at an exercise price of $137.75, vesting quarterly over four years.
• He also received 10,769 restricted stock units (RSUs), which vest over four years, with 25% vesting after one year and the remainder in three equal annual installments.
• Vested RSU shares will be delivered upon a change in control, separation of service, or seven years from the grant date.
• Additionally, Jacobson was granted 10,769 performance stock units (PSUs), which vest upon achievement of certain financial, regulatory, and developmental milestones.
• The filing indicates direct ownership of these securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating standard compensation practices. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of stock options, RSUs, and PSUs to the COO aligns his interests with the long-term success of the company.
• The vesting schedules for the options and units incentivize continued service and achievement of performance goals.

Future Outlook

The vesting of the RSUs is contingent upon a change in control, separation of service, or seven years from the grant date, while the PSUs vest upon achievement of certain financial, regulatory, and developmental performance milestones.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the pharmaceutical industry to incentivize executives.
• Vesting schedules are typically structured to align with long-term company performance and retention.

Stakeholder Impact

• The grants of stock options and units could potentially dilute existing shareholders' equity over time.
• The vesting schedules incentivize the COO to remain with the company and contribute to its success, which benefits shareholders.

Key Dates